Clinical Trials
20 trialsNCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02994784 2023-05-24
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Boston Medical Center
Phase 2 Terminated
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT00536601 2021-04-22
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Phase NA Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00075621 2020-09-17
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00651937 2020-01-14
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT00681044 2017-04-28
HD Melphalan and SCT in Patients With IGDD or LCDD
Boston Medical Center
Phase 2 Terminated
NCT00679367 2017-02-20
MRD
Boston Medical Center
Phase 2 Completed
NCT00790647 2017-02-06
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00075608 2017-01-27
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Phase 2 Terminated
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT00060255 2013-05-09
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Phase 2 Completed
NCT00089167 2013-01-16
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00004165 2012-06-06
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Northwestern University
Phase 3 Completed
NCT00621400 2011-05-10
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Nantes University Hospital
Phase 1/2 Completed
NCT00002810 2010-10-01
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
Temple University
Phase 2 Completed
NCT00344526 2007-06-28
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
University Hospital, Limoges
Phase 3 Completed